Latest News for PPTDF
PeptiDream Inc. (PPTDF) Q4 2025 Earnings Call Transcript
BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Curium Group today announced that together with PeptiDream Inc. and PDRadiopharma Inc., the first patient has been dosed in the companies' registrational clinical trial of 177Lu-PSMA-I&T in Japan for patients with PSMA (*1)-positive metastatic castration-resistant prostate cancer (mCRPC).
KAWASAKI, Japan--(BUSINESS WIRE)-- #IL17--PeptiDream is advancing the oral IL-17a/ IL-17F dual inhibitor peptide program into IND-enabling studies, while exploring strategic partnerships.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for PPTDF.
Senate Trading
No Senate trades found for PPTDF.
U.S. House Trading
No House trades found for PPTDF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.